July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

Ono gets local rights to Forty Seven's mAb
Forty Seven Inc. (NASDAQ:FTSV) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights in certain Asian territories to 5F9, a humanized mAb targeting CD47, as monotherapy or in combinations for all indications. The deal covers Japan, South Korea, Taiwan and some Southeast Asian countries. Forty Seven is to receive $15.8 million up front and is eligible for about $104 million in milestones, plus royalties. 5F9 is in clinical testing to treat a handful of cancers; the most advanced study is a Phase Ib/II trial to treat relapsed or refractory non-Hodgkin lymphoma (NHL).

Aimmune slips after ICER assesses peanut allergy treatments
Aimmune Therapeutics Inc. (NASDAQ:AIMT) lost $1.38 to $18.51 Thursday after the Institute for Clinical and Economic Review published its final evidence report on two treatments for peanut allergy, AR101 from Aimmune and Viaskin Peanut from DBV Technologies Inc. (NASDAQ:DBVT). An ICER panel voted 12-4 in June that the net health benefit of each of the treatments plus strict peanut avoidance was not superior to continued avoidance alone. ICER's conclusions regarding each therapy's cost-effectiveness threshold were generally consistent with its assessments in a draft evidence report published in April; both companies have said ICER's assessment is premature and does not incorporate enough evidence. DBV was off $0.07 to $10.65 (see "ICER Draft Report: Peanut Allergy")...